AAV-AQP1
Radiation-induced xerostomia
Phase 1Active
Key Facts
About MeiraGTx
MeiraGTx is focused on advancing a pipeline of gene therapies for serious conditions with high unmet medical need, primarily in ophthalmology and neurology. The company's core strength lies in its integrated platform encompassing vector design, promoter engineering, and manufacturing capabilities. Key strategic partnerships, including a significant collaboration with Janssen Pharmaceuticals, provide validation and resources for its lead programs. The company is navigating the complex clinical and regulatory pathway typical of gene therapy developers.
View full company profile